Navigation Links
Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
Date:2/11/2009

l judgment of the treating physician should guide the management plan of each patient based on individual benefit/risk assessment.

In postmarketing experience, severe and occasionally incapacitating bone, joint and/or muscle pain has been reported infrequently in patients taking bisphosphonates.

The most common adverse events (greater than or equal to 15%) in bone metastases clinical trials, regardless of causality, with Zometa 4 mg (n=1031) were as follows: bone pain (55%), nausea (46%), fatigue (39%), anemia (33%), pyrexia (32%), vomiting (32%), constipation (31%), dyspnea (27%), diarrhea (24%), weakness (24%), myalgia (23%), anorexia (22%), cough (22%), arthralgia (21%), lower-limb edema (21%), malignant neoplasm aggravated (20%), headache (19%), dizziness (excluding vertigo) (18%), insomnia (16%), decreased weight (16%), back pain (15%) and paresthesia (15%).

Caution is advised when bisphosphonates are administered with aminoglycosides, loop diuretics and potentially nephrotoxic drugs.

Zometa contains the same active ingredient as found in Reclast(R) (zoledronic acid). Patients being treated with Zometa should not be treated with Reclast.

Patients should be administered an oral calcium supplement of 500 mg and a multiple vitamin containing 400 IU of vitamin D daily.

Please see full Prescribing Information.

Disclaimer

The foregoing release contains forward-looking statements that can be identified by terminology such as "anticipate," "will," "might," "encouraging," "may" or similar expressions, or by express or implied discussions regarding potential new indications or labeling for Zometa or regarding potential future revenues from Zometa. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, unce
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
3. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
4. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
5. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
6. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
7. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
8. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
9. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
10. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
11. Video: Sanford Healths Journey to Cure Type 1 Diabetes Receives Major Boost
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of innovative medical-related ... their most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the ... the most litigious industry sectors of cases involving ...
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: PharmaPoint: ... Market Analysis to 2022 ... - India Drug Forecast and Market Analysis ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... reimbursement rates for home medical equipment and services (HME) ... as a result of Medicare,s bidding program going into ... largest metropolitan areas in the U.S. ... City, Miami, Orlando, Pittsburgh, and Riverside, California. The bidding ...
... Pa., Dec. 16, 2010 West Pharmaceutical Services, Inc. (NYSE: ... approved payment of the first-quarter 2011 cash dividend of $0.17 per ... shareholders of record on January 19, 2011. ... components and systems for injectable drug delivery, including stoppers and seals ...
Cached Medicine Technology:Problems Emerge in Competitive Bidding Pricing Scheme for Home Medical Equipment; Economists Predict the Program Will Fail 2Problems Emerge in Competitive Bidding Pricing Scheme for Home Medical Equipment; Economists Predict the Program Will Fail 3
(Date:4/17/2014)... Arias, M.D., Ph.D., at The University of Texas Health ... superbug that caused a bloodstream infection in a Brazilian ... of The New England Journal of Medicine . ... of highly-resistant bacteria known as methicillin-resistant Staphylococcus aureus ... hospital and community-associated infections. The superbug has also acquired ...
(Date:4/17/2014)... The world is less than 40 years away from ... people and governments, according to a top scientist at ... time in human history, food production will be limited ... water and energy," said Dr. Fred Davies, senior science ... issues could become as politically destabilizing by 2050 as ...
(Date:4/17/2014)... its status as the leading weapon against the deadly ... with new research indicating it simply needs to be ... of the cheap anti-malarial drug chloroquine in treating and ... more than half a million people each year around ... developed resistance to chloroquine, but research carried out at ...
(Date:4/16/2014)... A team that includes scientists from the School of ... San Antonio, Johns Hopkins University and St. Mary,s University reported ... to infect the body. , The fungal pathogen Candida ... and is the most common fungal pathogen to infect humans. ...
(Date:4/15/2014)... , , CHAMPAIGN, Ill. Scientists have solved a decades-old medical mystery ... way to fight invasive fungal infections, which kill about 1.5 million ... of action of amphotericin, an antifungal drug that has been in ... nearly as toxic to human cells as it is to the ...
Breaking Medicine News(10 mins):Health News:New MRSA superbug emerges in Brazil 2Health News:Food shortages could be most critical world issue by mid-century 2Health News:Scientists find new way to fight malaria drug resistance 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3
... physician and hospital is decreasing, study finds, , , TUESDAY, April ... physician would be the one who directed your health care ... comfort level. , But, in reality, that type of seamless ... Americans. , A new study found that among Medicare patients, ...
... pillow giveaway and Danny Seo appearance on HSN. , ... ... Earth Day, Simmons Bedding Company is encouraging consumers to ... the company,s Natural Care® mattress and pillow collection, which is endorsed ...
... RONKONKOMA, N.Y., April 21 NBTY, Inc. (NYSE: NTY ... marketer of nutritional supplements, today announced it will web cast a ... Web site, ( www.NBTY.com ), on Friday, April 24, ... for the fiscal second quarter will be issued at 4:30 PM ...
... CHAPEL HILL, N.C., April 21 New research with ... and managed markets is now available in the Best ... and consulting firm Best Practices, LLC.To review key topics ... links to each of the two new studies at ...
... WASHINGTON, April 21 FRC Action ... the Senate Finance Committee approved Gov. Kathleen Sebelius,s nomination ... vote on Gov. Sebelius,s nomination reflects growing grassroots opposition ... her failure to disclose deep financial ties to late-term ...
... Nursing baby brings cardiovascular benefits decades later, study suggests, ... just good for baby, it may also boost mom,s ... , Women in their 60s who had breast-fed for ... 10 percent less likely to develop cardiovascular disease, and ...
Cached Medicine News:Health News:Transition From Home to Hospital Rarely Seamless 2Health News:Transition From Home to Hospital Rarely Seamless 3Health News:Simmons Celebrates Earth Day by Encouraging Consumers To "Sleep Green" 2Health News:Simmons Celebrates Earth Day by Encouraging Consumers To "Sleep Green" 3Health News:Simmons Celebrates Earth Day by Encouraging Consumers To "Sleep Green" 4Health News:Simmons Celebrates Earth Day by Encouraging Consumers To "Sleep Green" 5Health News:NBTY to Web Cast Fiscal Second Quarter Conference Call 2Health News:NBTY to Web Cast Fiscal Second Quarter Conference Call 3Health News:Best Practice Database Adds Research Highlighting Effective Data Gathering Approaches for Competitive Intelligence and Successful Activities for Gaining Maximum Payer Access and Insights 2Health News:Breast-feeding a Boon to Mom's Heart 2Health News:Breast-feeding a Boon to Mom's Heart 3
The PHOS method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of phosphorus in serum....
For the quantitative in vitro determination of total and direct bilirubin in serum or plasma....
For the quantitative in vitro determination of Anti-Streptolysin-O (ASO) in serum...
For the quantitative in vitro determination of IgA in serum and plasma. This product is suitable for use on Hitachi 704, 705, 717, 902, 911 and 912....
Medicine Products: